OPKO Health (NASDAQ:OPK) Reaches New 12-Month High – Here’s Why

OPKO Health, Inc. (NASDAQ:OPK)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $1.6051 and last traded at $1.5750, with a volume of 1106308 shares. The stock had previously closed at $1.51.

Wall Street Analyst Weigh In

A number of analysts have issued reports on OPK shares. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Finally, Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $1.55.

OPKO Health Trading Up 1.3%

The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -5.67 and a beta of 1.50. The firm has a fifty day moving average price of $1.30 and a 200-day moving average price of $1.26.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $124.20 million during the quarter, compared to the consensus estimate of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.OPKO Health’s revenue for the quarter was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.29 EPS for the current year.

Institutional Trading of OPKO Health

A number of institutional investors and hedge funds have recently made changes to their positions in OPK. UBS Group AG increased its stake in OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock valued at $6,745,000 after acquiring an additional 577,248 shares during the last quarter. Norges Bank bought a new stake in OPKO Health during the second quarter worth $52,000. EP Wealth Advisors LLC bought a new stake in OPKO Health during the fourth quarter worth $37,000. Zacks Investment Management bought a new stake in OPKO Health during the fourth quarter worth $27,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of OPKO Health in the 1st quarter valued at $125,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.